Kasinger James R.'s Form 4 filing
CRISPR Therapeutics AG (CRSP) · filed Sep 24, 2026
- Accession no.
- 0001193125-26-401237
- Filed
- Sep 24, 2026, 5:35 PM ET
- Trade date
- Sep 22, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $626.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kasinger James R.CIK 0001708172 | Officer (General Counsel and Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Common Shares | MOption exerciseAcquired | +10,400 | $13.62 | +$141,648 | 105,184 | Direct | |
| Sep 22, 2026 | Common Shares | SSaleDisposed | −10,400 | $60.24 | −$626,459.6 | 94,784 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Common Shares | MOption exerciseDisposed | −10,400 | $0.00 | $0 | 83,232 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.